Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec;17(6):521-523.
doi: 10.1159/000528002. Epub 2022 Nov 10.

Evolution of HER2 Targeting in Metastatic Breast Cancer

Rupert Bartsch  1 , Marija Balic  2
Affiliations
Editorial

Evolution of HER2 Targeting in Metastatic Breast Cancer

Rupert Bartsch et al. Breast Care (Basel). 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Rupert Bartsch reports advisory roles at AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Grunenthal, MSD, Novartis, Pfizer, Pierre Fabre, Roche, and Seagen; lecture honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Grunenthal, MSD, Novartis, Pfizer, Pierre Fabre, Roche, and Seagen; and research support from Daiichi Sankyo. Marija Balic reports personal fees/travel support/from AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pfizer, Pierre Fabre, and Roche and research grants from AstraZeneca/Daiichi Sankyo, Eli Lilly, Novartis, Pierre Fabre, Pfizer, and Samsung.

References

    1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235((4785)):177–82. - PubMed
    1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344((11)):783–92. - PubMed
    1. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6((2)):117–27. - PubMed
    1. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10((17)):5650–5. - PubMed
    1. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382((7)):597–609. - PubMed

Publication types